Biocon Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Biocon Ltd's stock rose 3.52% to Rs 353.2, marking its third consecutive gain. The stock has increased 4.22% over the past year, outperforming NIFTY and Nifty Pharma index gains. Monthly gains stand at 7.63%, with trading volume significantly above average.

Biocon Ltd Gains for Third Straight Session - 11 Jun, 2025

Biocon Foundation, in collaboration with NCBS and BeST Cluster, has launched the BioWISE initiative to support 25 women science students in Karnataka through scholarships and mentorship.

Biocon Launches BioWISE Program for Women in STEM - 09 Jun, 2025

Biocon has doubled its insulin manufacturing capacity in Malaysia, positioning itself as a key player in the market. Chairperson Kiran Mazumdar-Shaw anticipates significant growth in FY26, driven by rising global demand for insulin.

Biocon Doubles Insulin Capacity, Sees Growth Ahead - 06 Jun, 2025

Biocon secures CDSCO approval for Liraglutide, a significant diabetes treatment. CEO Kiran Mazumdar Shaw emphasizes Biocon's strategy to dominate the diabesity market and expand its GLP-1 pipeline.

Biocon Advances Diabetes Treatment with Key Approvals - 02 Jun, 2025

Biocon Biologics Ltd has received marketing authorization from the UK's MHRA for YESINTEK®, a biosimilar for Ustekinumab, approved for treating psoriasis and other conditions. This follows recent EU approval, enhancing access to biosimilars.

Biocon Biologics Receives UK Approval for YESINTEK® - 25 May, 2025

Biocon Biologics has received a six-month extension for its insulin supply contract with the Malaysian government, now valid until October 28, 2025. This extension reinforces Biocon's commitment to providing affordable insulin access in Malaysia and globally.

Biocon Secures Extension for Malaysian Insulin Supply - 22 May, 2025

Biocon Biologics successfully launched its Ustekinumab BS Subcutaneous Injection in Japan, leading to a 2% rise in Biocon shares. The biosimilar targets psoriasis and psoriatic arthritis, expanding Biocon's market presence after previous launches in the US and Europe. Strong quarterly results further support investor confidence.

Biocon Launches Ustekinumab Biosimilar in Japan - 21 May, 2025

Biocon Ltd shares rose 1.3% today, marking the fifth consecutive session of gains. The stock is currently priced at Rs 343.8, up 11.77% over the past year, outperforming the NIFTY and Nifty Pharma indices. Volume is lower than average, with 7.5 lakh shares traded today.

Biocon Ltd Continues Upward Trend for Fifth Session - 19 May, 2025

Biocon's subsidiary, Biocon Pharma, has received US FDA approval for Rivaroxaban Tablets, strengthening its portfolio. The company reported a 154.24% profit surge in Q4 FY25.

Biocon Pharma Secures FDA Approval for Rivaroxaban - 16 May, 2025

Biocon is set to raise ₹4,500 crore through a QIP to enhance its stake in Biocon Biologics. Investec has initiated a 'buy' rating, emphasizing growth in biosimilars. CEO Siddharth Mittal noted strong momentum across business segments and opportunities in the GLP market.

Biocon's Growth Prospects and Fundraising Plans Highlighted - 15 May, 2025

Biocon is exploring a merger of its biosimilars unit while postponing IPO plans due to market volatility. Despite this, shares rose 2.11%. ICICI Securities maintains a Sell rating with a revised target price of Rs 270, citing margin concerns.

Biocon Evaluates Merger, Stock Shows Positive Movement - 14 May, 2025

Biocon's leadership projects mid-teens revenue growth for FY26, driven by strong performance in biosimilars and generics. Citigroup maintains a buy rating despite recent challenges.

Biocon Projects Mid-Teens Revenue Growth - 13 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 8.58% to 8.77% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 7 days, BIOCON stock has moved up by 5.1%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Revenue is up for the last 3 quarters, 3.64K Cr → 4.47K Cr (in ₹), with an average increase of 9.6% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 3 quarters, -16.0 Cr → 344.5 Cr (in ₹), with an average increase of 128.2% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Foreign Institutions holdings remained unchanged at 5.66% of holdings in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Unchanged

Promoters holdings remained unchanged at 60.64% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 3 years, Vimta Labs Ltd has given 223.6% return, outperforming this stock by 214.7%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

In the last 1 year, Vimta Labs Ltd has given 104.5% return, outperforming this stock by 98.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Retail Investor have decreased holdings from 18.12% to 17.76% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

NIFTY PHARMA

S&P BSE 250 LargeMidCap

Nifty Midcap 100

BSE Mid-Cap

BSE 200

Nifty Midcap 150

Nifty 200

Nifty LargeMidcap 250

Nifty 500

Nifty Healthcare

Nifty MidSmallcap 400

S&P BSE 150 MidCap

S&P BSE 400 MidSmallCap

BSE Healthcare

BSE 500

SBI Contra Fund Direct Growth

Kotak Equity Opportunities Direct Growth

SBI Balanced Advantage Fund Direct Growth

SBI Magnum Midcap Fund Direct Growth

Nippon India Focused Equity Fund - Direct Plan - Growth Option

Biocon Ltd’s net profit jumped 154.24% since last year same period to ₹344.50Cr in the Q4 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 1272.51% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.94	Bullish
CCI (20)	-94.05	Neutral
RSI (14)	79.48	Bearish
Momentum (10)	3.25	Bullish
ADI (14)	32.91	Bullish
Ultimate Oscillator (7,14,28)	90.51	Bullish

Name	Value	Action
SMA (20)	355.22	Bullish
EMA (20)	355.6	Bullish
VWMA (20)	355.86	Bullish
SMA (50)	354.12	Bullish
EMA (50)	354.59	Bullish
SMA (200)	352.12	Bullish
EMA (200)	353.21	Bullish
KAMA (200)	354.31	Bullish
DEMA (200)	353.9	Bullish

Biocon Ltd (BIOCON)

Summary

Overall

Oscillators

Moving Averages